Related Experiment Videos
[Brachytherapy of local prostatic carcinoma]
1Urologische Klinik der Charité, Humboldt Universität, Campus Mitte, Schumannstrasse 20/21, 10098 Berlin. serdar.deger@charite.de
Der Urologe. Ausg. A
|June 19, 2001
Summary
Brachytherapy for prostate cancer in Germany utilizes various radioactive sources like iodine-125 and palladium-103 for permanent implants. Patient selection is crucial for successful low-dose rate brachytherapy, especially for low-risk individuals.
Area of Science:
- Oncology
- Medical Physics
- Radiotherapy
Context:
- Brachytherapy for prostate cancer is increasingly utilized in Germany.
- Multiple radioactive sources (e.g., Iodine-125, Palladium-103, Gold-198 for permanent; Iridium for temporary) are available.
- Both low-dose rate (LDR) and high-dose rate (HDR) brachytherapy techniques are employed, differing in dose distribution and patient suitability.
Purpose:
- To outline the current landscape of prostate cancer brachytherapy in Germany.
- To differentiate between permanent and temporary radioactive implant sources.
- To define patient selection criteria for effective LDR brachytherapy.
Summary:
- Permanent brachytherapy sources commonly used in Germany include Iodine-125, Palladium-103, and Gold-198, while Iridium is used for temporary implants.
- LDR and HDR brachytherapy techniques vary in their dose delivery and the patient populations they serve.
- Optimal candidates for LDR monotherapy are low-risk patients with PSA < 10 ng/ml, T2b stage, and Gleason score < 7.
Impact:
- Highlights the importance of appropriate radioactive source selection for specific brachytherapy techniques.
- Emphasizes the critical role of patient selection in achieving successful prostate cancer brachytherapy outcomes.
- Provides guidance for clinicians on identifying suitable candidates for LDR brachytherapy monotherapy.